Innate Immunotherapeutics (ASX:IIL) CEO Simon Wilkinson told investors Innate Immunotherapeutics is a phase 2 company treating Secondary Progressive Multiple Sclerosis.
Mr Wilkinson shared the company’s investment thesis. The company’s lead drug candidate MIS416 will complete a Phase 2B placebo controlled trial for Secondary Progressive Multiple Sclerosis in April next year.
Simon also discussed the market opportunity which lies in unmet medical needs pertaining to Secondary Progressive Multiple Sclerosis. There are currently no approved disease modifying drugs. Innate Immunotherapeutics judge that potential annual market revenues could total $US4 billion.
